NH1,902.90

Narayana Hrudayalaya Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISNEULANDLABNATCOPHARMLALPATHLABSAILIFECOHANCEMcap ₹38,888 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations5,018.25,483.07,896.09,072.4
Other Income75.292.0100.2111.9
Total Income5,093.45,575.07,996.39,184.3
Expenses
+ Purchases of Stock-in-Trade1,112.31,140.91,560.41,775.3
+ Changes in Inventories-38.4-4.5-44.3-50.7
+ Employee Benefit Expense1,004.31,092.71,803.02,232.3
+ Finance Costs96.9146.4243.7285.4
+ Depreciation & Amortisation242.1278.1447.8519.6
+ Other Expenses1,787.71,977.52,960.33,366.1
Total Expenses4,204.94,631.16,970.98,127.9
EBITDA1,152.41,276.41,616.71,749.4
EBIT910.2998.31,168.91,229.8
Profit
PBT before Exceptional Items888.5943.91,025.31,056.4
+ Exceptional Items0.0-8.4-51.0-51.0
Pretax Income888.5935.5974.41,005.4
+ Current Tax137.6129.8176.6198.1
+ Deferred Tax-38.715.9-18.2-21.5
Tax Expense98.9145.7158.4176.7
Net Income789.6790.6806.0816.5
+ Net Income — Continuing Ops789.6789.8810.5821.7
+ Net Income — Discontinued Ops0.00.8-4.5-5.1
+ Other Comprehensive Income13.833.8196.7182.9
Total Comprehensive Income803.4824.41,002.7999.5
Net Income to Common789.3790.2805.6816.1
Minority Interest0.40.50.40.4
Per Share
Basic EPS38.8638.9039.6740.18
Diluted EPS38.8638.9039.6740.18
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.01.5-3.7-4.4
+ Tax — Discontinued Operations0.00.70.80.7
Other Comprehensive Income — detail
+ Other Comprehensive Income33.8196.7182.9
+ Items NOT to be Reclassified to P&L-3.3-5.3-1.4-8.8
+ Tax on Items NOT to be Reclassified-1.60.3-0.7
+ Tax on Items NOT to be Reclassified — alt tag-0.8
+ Items to be Reclassified to P&L16.137.4198.4191.1
+ Tax on Items to be Reclassified-0.00.0-0.0
+ Tax on Items to be Reclassified — alt tag-0.1
+ Net Movement — Regulatory Deferral Balances0.00.0-5.6-7.0
Comprehensive Income — Owners of Parent13.833.81,002.3999.1
Comprehensive Income — Non-controlling Interests-0.0-0.00.40.4
Per Share — as-filed variants
Basic EPS — Continuing Operations38.8638.8639.8940.43
Diluted EPS — Continuing Operations38.8638.8639.8940.43
Basic EPS — Discontinued Operations0.000.04-0.22-0.25
Diluted EPS — Discontinued Operations0.000.04-0.22-0.25
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit3,944.34,346.66,379.97,347.8
Gross Margin %78.6079.2780.8080.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)888.5943.91,025.31,056.4
− Exceptional Items (reconciliation)0.0-8.4-51.0-51.0
Net Income Adj (tax-effected)789.6797.7848.7858.5
EPS Adj38.8639.2541.7742.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Filed Debt Equity0.010.010.010.01
Filed Dscr0.030.030.020.02
Filed Iscr0.100.070.050.04
Paid Up Equity Capital204.4204.4204.4204.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.